Why SK Life Science Labs’ AACR 2026 data could put targeted protein degradation back in the oncology spotlight
What Doximity (NYSE: DOCS) CFO resignation means for governance, capital allocation, and investor confidence
Read More General business news Why Wagners stock may be building a bullish case after A$30m placement and FY25 results Wagners (ASX:WGN) raises A$30M to fund plant expansion and composite fibre growth. Find out what FY25 results reveal about its stock momentum and FY26 outlook. byPallavi MadhirajuSeptember 8, 2025